logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
20/08/2025
Reserve Bank of New Zealand: The 250 basis points of easing in the past will support economic growth.
Latest
3 m ago
On August 20, Novartis announced that its innovative product Nuralda (Arquerant hydrochloride tablets) has been approved by the National Medical Products Administration for the reduction of proteinuria in adult patients with primary IgA nephropathy who are at risk of rapid disease progression. It is reported that Nuralda is the first non-immunological therapy approved in China for the treatment of IgA nephropathy. It is also the first and currently the only highly selective endothelin A (ETA) receptor antagonist for this indication in the country.
3 m ago
Novartis' innovative drug Nolasiban has been approved for the treatment of IgA nephropathy in China.
3 m ago
Britain's inflation accelerates and hits an 18-month high, central bank may reconsider interest rate cuts
4 m ago
The stock price of Cambrian has once again broken through 1,000 yuan, making it the second stock above 1,000 yuan in the current market.
5 m ago
Hongtian stock hit the daily limit up.
See all latestmore
logo
Contact US
qr
+852 - 60190728
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.